Sulfoximide compound and application thereof

By designing sulfinimide compounds, the structural limitations and safety of existing GLP-1 receptor small molecule agonists were solved, and significant GLP-1 receptor agonism activity and liver microsomal stability were achieved, providing The novel GLP-1 receptor agonist has improved the therapeutic effect and patient compliance.

CN119019428APending Publication Date: 2024-11-26CHINA PHARM UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411136389.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The structural types of existing GLP-1 receptor small molecule agonists are limited, with low safety, large side effects, and low glycemic and weight loss effects. Patient compliance is poor. It is necessary to develop new structural types, low side effects and good patient compliance. GLP-1 receptor agonist.

Method used

A sulfinimide compound was designed with specific GLP-1 receptor agonism activity. A series of derivatives were synthesized through reasonable drug design. The biological activity evaluation showed that the designed compound had significant GLP-1 receptor agonism. activity and has better hepatic microsomal stability than the positive control Orforglipon.

Benefits of technology

Achieving significant GLP-1 receptor agonism activity and better liver microsomal stability provides a new structural type of GLP-1 receptor agonist with potential applications for the treatment of type 2 diabetes and related diseases, improving Patient compliance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019428A_ABST
    Figure CN119019428A_ABST
Patent Text Reader

Abstract

The invention discloses a sulfoximide compound and an application of the sulfoximide compound. The structure of the compound is shown in a formula I, and the compound further comprises pharmaceutically acceptable salt, stereoisomer, solvate or hydrate of the compound. The compound and the pharmaceutical composition thereof are agonists of a glucagon-like peptide-1 receptor (GLP-1R), and have a relatively good treatment effect on non-insulin-dependent diabetes mellitus (type 2 diabetes mellitus), obesity and the like. Therefore, the sulfoximide compound disclosed by the invention can be used for preparing medicines for preventing and / or treating GLP-1 mediated diseases or related diseases. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and specifically relates to a sulfenyl imide compound and its application. The compound can be used as a GLP-1 receptor agonist for preparing a drug for preventing or treating GLP-1-mediated diseases and related diseases. Background Art

[0002] The prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide, closely associated with increasing waist circumference and the number of people who are overweight and obese. The landmark United Kingdom Prospective Diabetes Study (UKPDS) provided the first high-quality evidence that improving glycemic control in patients with new-onset T2DM can ultimately reduce the incidence of microvascular complications and long-term macrovascular disease. To date, many new drugs have been developed and subsequently marketed for the treatment of T2DM, which effectively lower blood glucose levels while minimizing the risk of hypoglycemia and reducing weight.

[0003] Glucagon-like peptide-1 (GLP-1) is a neuroendocrine hormone derived from the proglucagon precursor. Proglucagon is a protein expressed in enteroendocrine cells, pancreatic alpha cells, and the nucleus tractus solitarius (NTS) of the brainstem. In the pancreas, proglucagon undergoes post-translational processing by prohormone convertase 2 to produce glucagon, GRPP, and major proglucagon fragment (MPGF). A small amount (10-20%) of MPGF is cleaved to produce GLP-1.

[0004] GLP-1 has long been recognized as a potent stimulator of insulin secretion and a key regulator of energy homeostasis. GLP-1 receptors are distributed in the gastrointestinal tract, pancreas, vagal afferent nerves, and central nervous system. Activation of GLP-1 receptors (GLP-1R) by GLP-1 stimulates insulin release and inhibits glucagon secretion in a glucose-dependent manner, thereby lowering blood glucose. In addition, agonizing GLP-1R delays gastric emptying, increases satiety, inhibits food intake, and reduces body weight in humans. Recently, GLP-1 in the brain has been increasingly recognized to participate in a series of neural circuits to regulate appetite and reward-related behaviors, thereby achieving the effect of lowering blood glucose.

[0005] The GLP-1 receptor agonists developed in the early stage are GLP-1 analogs, all of which belong to peptide substances, including liraglutide, semaglutide, etc. One disadvantage is that they need to be injected. Oral semaglutide has been shown to effectively lower blood sugar levels and is generally well tolerated. However, oral peptides are still limited by a variety of unfavorable factors such as administration time, dosage, gastrointestinal disturbance, etc., and the bioavailability is very low, only 1%, and patient compliance is poor. In recent years, researchers have found that the function of GLP-1 receptors can also be regulated by small molecule compounds, and then GLP-1 receptor small molecule agonists have been developed, including Pfizer, Chugai Pharmaceutical / Eli Lilly and other oral GLP-1 receptor small molecule agonists. However, the structural types of existing small molecule agonists are limited, and the safety of GLP-1 receptors is not high, the side effects are large, and the hypoglycemic and weight loss effects are not obvious. Therefore, it is very necessary to develop GLP-1 receptor agonists with new structural types, low side effects, and good patient compliance.

[0006] The development of new GLP-1 receptor small molecule drugs is urgent. Summary of the invention

[0007] Purpose of the invention: The present invention aims to provide a sulfenyl imine compound having specific GLP-1 receptor agonist activity and its application.

[0008] One of the objects of the present invention is to provide a sulfenyl imine compound of formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or hydrate thereof:

[0009]

[0010] in,

[0011] Ring A is C 3-6 Cycloalkyl, C 6-10 Aryl or C 5-10 Heteroaryl; the cycloalkyl, aryl or heteroaryl may be optionally substituted by 1 to 5 independently selected from halogen, CN, NO2, C 1-6 Alkyl, C 3-6 Cycloalkyl or C 1-6 The substituent of the alkoxy group is substituted; the C 1-6 The alkyl group is optionally substituted with one or more halogen atoms;

[0012] Ring B is phenyl, C 5-6 Heteroaryl or C 4-7 Heterocyclic group; the phenyl, heteroaryl or heterocyclic group may be optionally replaced by R 3 replace;

[0013] R 1 Selected from hydrogen, deuterium, CN, C 1-6 Alkyl, C 3-6 Cycloalkyl or C4-7 Heterocyclic group; the alkyl, cycloalkyl, heterocyclic group can be optionally substituted by halogen, CN, hydroxyl, C 1-3 Alkyl, C 3-6 Cycloalkyl, C 4-7 Heterocyclyl substitution;

[0014] R 2 Selected from C 1-6 Alkyl, C 3-6 Cycloalkyl or C 4-7 Heterocyclic group, or R 1 , R 2 The atoms connected to it together form a 5-7 membered heterocyclic group; the alkyl, cycloalkyl, heterocyclic group can be optionally substituted by halogen, CN, hydroxyl, C 1-3 Alkyl, C 3-6 Cycloalkyl, 4-7 membered heterocyclic substitution;

[0015] R 3 Selected from H, halogen, hydroxyl, -CN, -NO2, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -NHC 3-6 Cycloalkyl, -N(C 1-6 Alkyl)(C 3-6 Cycloalkyl), -C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -OC 3-6 Cycloalkyl, -OC 4-6 Heterocyclic group, -C(O)C 1-6 Alkyl, -C(O)C 4-6 Heterocyclic group, -CONH2, -CONH(C 1-6 Alkyl), -CON(C 1-6 Alkyl)2, -CONHC 3-6 Cycloalkyl, -CONHC 4-6 Heterocyclic group, -NHCOC 1-6 Alkyl, -NHCOOC 1-6 Alkyl, -NHCOC 3-6 Cycloalkyl, -NHCOOC 4-6 Heterocyclic group, -S(O)(=NC 1-6 Alkyl)C 1-6 Alkyl, -N=S(O)(C 1-6 Alkyl)2, -P(O)(C 1-6 Alkyl)2, C 1-6 Alkyl, C 3-8 Cycloalkyl, C 1-6 Alkoxy, C 6-10 Aryl, C 5-10 Heteroaryl or C3-8 Heterocyclic group, or R 2 , R 3 Together with the atoms to which it is attached, it forms a 5-7 membered heterocyclic group; or R 1 , R 3 The atoms to which it is attached together form a 5-7 membered heterocyclic group; the alkyl, cycloalkyl, alkenyl, alkynyl, heterocyclic group, aryl or heteroaryl group may be optionally substituted by halogen, CN, hydroxyl, amino, nitro, acyl, C 1-6 Alkyl, -OC 1-6 Alkyl, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, C 3-6 Cycloalkyl, C 4-7 Heterocyclyl substitution;

[0016] L 1 Does not exist, or L 1 Selected from (CH2) n -、-CH 0-1 R 4 (CH2) n -、-(CH2) n -O-CHR 4 -、

[0017] -(CH2) n -NH-CHR 4 -; where R 4 is selected from hydrogen, halogen, hydroxy, alkyl, haloalkyl, alkoxy, haloalkoxy, alkoxyalkyl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl or alkylheterocycloalkyl;

[0018] L 2 Selected from -C(=O)-, -CHR 5 - or -S(=O)2-; wherein R 5 is hydrogen, halogen or C 1-6 alkyl;

[0019] Ring C is selected from the following groups:

[0020]

[0021] R 6 , R 7 , R 8 , R 9 are independently selected from hydrogen, halogen or C 1-6 alkyl;

[0022] L 3 Does not exist, or L 3 Selected from -CH2-;

[0023] L 4Does not exist, or L 4 Selected from -CH2-;

[0024] R 10a , R 10b are independently selected from hydrogen or C 1-6 Alkyl, where C 1-6 The alkyl group may be substituted with one or more halogen or C 1-6 Alkoxy substituted; or R 10a , R 10b Together with the carbon atoms to which they are attached, they can form C 3-15 Cycloalkyl, wherein C 3-15 The cycloalkyl group may be optionally substituted with halogen, CN, hydroxy, amino, nitro, C 1-3 Alkyl, C 3-6 Cycloalkyl, 4-7 membered heterocyclic substitution;

[0025] R 11 Selected from the following groups:

[0026]

[0027] R 12a , R 12b , R 12c , R 12d , R 12e are each independently selected from hydrogen, C 1-6 Alkyl; among which C 1-6 The alkyl group may be substituted with one or more halogen or C 1-6 Alkoxy substitution;

[0028] Ring D is C 3-12 Heterocyclic group, C 5-6 Heteroaryl; the heterocyclic group, heteroaryl group can be optionally substituted by halogen, CN, hydroxyl, amino, nitro, C 1-6 Alkyl, C 3-15 Cycloalkyl, C 4-7 Heterocyclyl substitution;

[0029] n=0, 1 or 2.

[0030] The present invention synthesizes a series of derivatives through reasonable drug design, and biological activity evaluation shows that the designed compounds have significant GLP-1 receptor agonist activity.

[0031] In certain preferred embodiments,

[0032] Ring C is selected from:

[0033]

[0034] In certain preferred embodiments,

[0035] Ring D is selected from:

[0036]

[0037] The compound of formula I of the present invention or its pharmaceutically acceptable salt, stereoisomer, solvate or hydrate, preferably has a structure shown in formula Ia or formula Ib:

[0038]

[0039] in,

[0040] Ring A, Ring B, R 1 , R 2 , L 1 As defined in Formula I.

[0041] In certain further preferred embodiments,

[0042] Ring A is selected from phenyl or C 5-6 heteroaryl, and the phenyl or heteroaryl is substituted by 1 to 4 independently selected from halogen, C 1-6 Alkyl or C 3-6 The cycloalkyl group is substituted with a substituent.

[0043] In certain further preferred embodiments,

[0044] Structural unit

[0045] Selected from:

[0046]

[0047]

[0048] In certain preferred embodiments,

[0049] Ring C is selected from the following groups:

[0050]

[0051] R 6 , R 7 , R 8 , R 9 Selected from hydrogen;

[0052] L 3 does not exist;

[0053] L 4 does not exist;

[0054] R 10a , R 10b are independently selected from hydrogen or C 3-15 Cycloalkane ring;

[0055] R 11 Selected from the following groups:

[0056]

[0057] In certain further preferred embodiments,

[0058] Ring C is selected from:

[0059]

[0060] In certain further preferred embodiments,

[0061] Ring D is selected from:

[0062]

[0063] In some preferred embodiments, the compound represented by Formula I is contacted with or reacted with an acid or a base, which can be used for the preparation of a pharmaceutical preparation, to obtain a salt thereof. The salt may be any pharmaceutically acceptable salt, and examples of the salt include inorganic acid salts (hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, etc.), sulfonates (methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, etc.), carboxylates (formates, acetates, oxalates, maleates, fumarates, citrates, malates, succinates, malonates, gluconates, mandelates, benzoates, salicylates, fluoroacetates, trifluoroacetates, tartrates, propionates, glutarates, adipates, nicotinates, etc.), alkali metal salts (lithium salts, sodium salts, potassium salts, cesium salts, etc.), alkaline earth metal salts (magnesium salts, calcium salts, etc.), ammonium salts and basic amino acid salts (lysine salts, arginine salts, etc.), and alkali metal salts and alkaline earth metal salts are preferred, more preferably sodium salts and calcium salts. For example, the free form of the compound represented by Formula I can be suspended or dissolved in an alcohol such as methanol or acetonitrile, acetone, etc., and an alkaline aqueous solution containing sodium ions derived from sodium hydroxide, etc., a methanol solution containing sodium methoxide, or an ethanol solution containing sodium ethoxide is added thereto to obtain the sodium salt of the compound represented by Formula I.

[0064] The compounds of formula I of the present invention are preferably the following compounds:

[0065]

[0066]

[0067]

[0068]

[0069]

[0070]

[0071] The above-mentioned compounds of formula I of the present invention may also exist in the form of their salts, hydrates, solvates, which are converted into compounds of formula I in vivo. For example, within the scope of the present invention, the compounds of the present invention are converted into pharmaceutically acceptable salt forms according to processes known in the art, and they are used in the form of salts.

[0072] All tautomeric forms of the compounds of formula I of the present invention are included within the scope of the present invention. The compounds of the present invention may exist in specific geometric or stereoisomer forms. Additional asymmetric carbon atoms may exist in substituents such as alkyl, and all these isomers and their mixtures are included within the scope of the present invention.

[0073] Another object of the present invention is to provide a pharmaceutical composition, which comprises a compound of formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or hydrate thereof and a pharmaceutically acceptable carrier.

[0074] The pharmaceutical composition of the present invention can be administered in various known ways, such as orally, parenterally, by inhalation spray or via an implanted reservoir. The pharmaceutical composition of the present invention can be administered alone or in combination with other drugs. Oral compositions can be in any orally acceptable dosage form, including but not limited to tablets, capsules, emulsions, suspensions, dispersions and solutions. Commonly used pharmaceutically acceptable carriers or excipients include stabilizers, diluents, surfactants, lubricants, antioxidants, adhesives, colorants, fillers, emulsifiers, etc.

[0075] Sterile injectable compositions can be formulated using suitable dispersing agents or wetting agents and suspending agents according to techniques known in the art. Pharmaceutically acceptable carriers and solvents that can be used include water, mannitol, sodium chloride solution, and the like.

[0076] The actual dosage level of the active ingredient in the pharmaceutical composition of the present invention can be varied to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The selected dosage level depends on a variety of factors, including the activity of the specific compound of the present invention or its salt used, the route of administration, the time of administration, the excretion rate of the specific composition used, the duration of treatment, other drugs, compounds and / or materials used in combination with the specific composition used, the age, sex, weight, general health and previous medical history of the patient being treated, and similar factors well known in the medical field.

[0077] Another object of the present invention is to provide the use of the compound of formula I or its pharmaceutically acceptable salt, stereoisomer, solvate or hydrate in the preparation of a medicament for preventing and / or treating GLP-1-mediated diseases or related diseases.

[0078] The GLP-1 mediated diseases or related diseases include diabetes, hyperglycemia, insulin resistance, glucose intolerance, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, adipocyte dysfunction, obesity, dyslipidemia, and hyperinsulinemia.

[0079] Wherein, the diabetes includes T1D and / or T2DM, idiopathic T1D, early-onset T2DM, latent autoimmune diabetes, juvenile atypical diabetes or gestational diabetes.

[0080] Beneficial effects:

[0081] (1) The compound of formula I prepared by the present invention and its pharmaceutically acceptable salt, stereoisomer, solvate or hydrate have significant agonist activity on GLP-1 receptor. Therefore, the above compound can be used to prepare a drug for preventing and / or treating GLP-1-mediated diseases or related diseases.

[0082] (2) The preparation method of the compound of the present invention is simple and easy to operate.

[0083] (3) The compounds of the present invention have better liver microsomal stability than the positive control Orforglipon. DETAILED DESCRIPTION

[0084] The preparation method of the compound of general formula I of the present invention is described below in conjunction with specific examples, but these specific methods do not constitute any limitation to the present invention. The compound of the present invention can also be conveniently prepared by optionally combining various synthetic methods described in this specification or known in the art, and such a combination can be easily carried out by a technician in the field to which the present invention belongs.

[0085] The starting materials, reaction reagents, etc. used in the specific examples of the present invention are all commercially available.

[0086] (1) Synthesis of intermediate 1g:

[0087]

[0088] Step 1-1:

[0089] (S)-3-(Boc-amino)butyric acid 1a (50.0 g, 246 mmol) was dissolved in THF (800 mL), and HATU (112.5 g, 295 mmol) and DIPEA (95 g, 737.5 mmol) were added in sequence. After stirring for 10 min, NH4Cl (33 g, 615 mmol) was added. The mixture was stirred at 25 °C for 8 h, then diluted with ethyl acetate (500 mL), washed with water (200 mL×3), washed with saturated brine (200 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain intermediate 1b as a light yellow solid (100 g, crude product), which was used in the next step without purification. HR-MS (ESI + Calculated value: C9H 18 N2O3[M+H] + :203.1351, measured value 203.1331.

[0090] Step 1-2:

[0091] The intermediate 1b (100g, crude product) was dissolved in pyridine (80mL, 990mmol), cooled to 10°C, and TFAA (69mL, 495mmol) was slowly added dropwise, keeping the temperature not higher than 15°C. After the addition was completed, the temperature was raised to 25°C and stirred for 1h. After TLC monitoring, the reaction was completed, saturated Na2CO3 solution (300mL) was added to quench, and ethyl acetate (300mL×3) was used for extraction. The organic phases were combined, washed with saturated brine (500mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 15:1, v / v) to obtain intermediate 1c (35g, two-step yield 77%) as a white solid. HR-MS (ESI + Calculated value: C9H 16 N2O2[M+H] + :185.1245, measured value 185.1222.

[0092] Steps 1-3:

[0093] A hydrochloric acid solution of dioxane (4N, 350 mL) was added to the intermediate 1c (35 g, 190 mmol), and the mixture was stirred at room temperature for 10 min. After the reaction was completed as monitored by TLC, the mixture was filtered off with suction, and the filter cake was washed with dioxane and dried to obtain the hydrochloride of the intermediate 1d as a white solid (20 g, yield 87%). 1 H NMR (300MHz, DMSO-d6) δ = 8.58 (br.s, 2H), 3.56 (m, 1H), 3.09-2.89 (m, 2H), 1.34-1.32 (m, 3H) ppm. HR-MS(ESI + ): Calculated value C4H8N2[M+H]+ :85.0721, measured value 85.0711.

[0094] Steps 1-4:

[0095] Intermediate 1d (3.16 g, 26.2 mmol) was dissolved in EtOH (20 mL), and TEA (3.95 g, 39.3 mmol) and ethyl acrylate (2.63 g, 26.2 mmol) were added in sequence. The mixture was stirred at 70 °C for 2 h. After the reaction was completed as monitored by TLC, the reaction mixture was cooled to room temperature to obtain intermediate 1e. The product was used in the next step without post-treatment. HR-MS (ESI + Calculated value: C9H 16 N2O2[M+H] + :185.1245, measured value 185.1221.

[0096] Steps 1-5:

[0097] The reaction solution from the previous step was added to (Boc)2O (6.86 g, 31.4 mmol) and stirred at room temperature overnight. Diluted with water (50 mL), extracted with ethyl acetate (50 mL × 3), combined organic phases, washed with saturated brine (20 mL), dried over anhydrous Na2SO4, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 10: 1 v / v) to obtain intermediate 1f (3.38 g, yield 70%) as a yellow oil. HR-MS (ESI + ): Calculated value C 14 H 24 N2O4[M+H] + :285.1770, measured value 285.1769.

[0098] Steps 1-6:

[0099] The intermediate 1f (0.70 g, 2.46 mmol) was dissolved in THF (15 mL), t-BuOK (0.28 g, 2.46 mmol) was added and stirred at room temperature for 1 h. After the reaction was completed by TLC monitoring, it was quenched with 2N HCl solution (2 mL), diluted with H2O (20 mL), extracted with ethyl acetate (20 mL×3), the organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 8: 1 v / v) to obtain the intermediate 1g (0.5 g, yield 85%) as a light yellow solid. 1H NMR (300MHz, DMSO-d6) δ = 4.56 (m, 1H), 3.93-4.10 (m, 1H), 3.02-3.18 (m, 1H), 2.57 (m, 1H), 2.05-2.42 (m, 2H), 1.47 (s, 9H), 1.26-1.28 (m, 3H)ppm. HR-MS(ESI + ): Calculated value C 12 H 18 N2O3[M+H] + :239.1351, measured value 239.1333.

[0100] (2) Synthesis of intermediate 2d:

[0101]

[0102] Step 2-1:

[0103] 3-Bromo-4-fluoroaniline 2a (16.6 g, 87.4 mmol) was dissolved in toluene (200 mL), and cyclopropylboric acid (8.6 g, 113.6 mmol), tripotassium phosphate (64.8 g, 305.8 mmol) dissolved in H2O (100 mL), tricyclohexylphosphine (2.4 g, 8.74 mmol), and palladium acetate (1 g, 4.37 mmol) were added in sequence. The mixture was stirred at 100 °C for 12 h under nitrogen atmosphere. After the reaction was completed by TLC monitoring, the mixture was filtered, and the filtrate was diluted with H2O (100 mL), extracted with ethyl acetate (200 mL×3), and the organic phases were combined, washed with saturated brine (200 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 6:1, v / v) to obtain intermediate 2b (10 g, yield 75%) as a yellow oil. HR-MS (ESI + Calculated value: C9H 10 FN[M+H] + :152.0831, measured value 152.0833.

[0104] Step 2-2:

[0105] Concentrated hydrochloric acid (25 mL) was added to the intermediate 2b (5 g, 33.1 mmol), the temperature was lowered to 0°C, and NaNO2 (2.6 g, 39.7 mmol) dissolved in water (50 mL) was added dropwise, the temperature was kept below 5°C, and the mixture was stirred at 0°C for 0.5 h. After the reaction was complete as monitored by TLC, SnCl2 (17.8 g, 99.2 mmol) dissolved in concentrated hydrochloric acid (25 mL) was added, the temperature was kept below 5°C, and the mixture was stirred at 0°C for 1 h. After the reaction was complete as monitored by TLC, the pH was adjusted to 9 with a saturated NaOH solution, and a large amount of floccules precipitated. After filtration, the filtrate was extracted with ethyl acetate (100 mL × 3), the organic phases were combined, washed with saturated brine (200 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a yellow oily intermediate 2c. The crude product was used in the next step without purification. HR-MS (ESI + Calculated value: C9H 11 FN2[M+H] + :167.0940, measured value 167.0946.

[0106] Step 2-3:

[0107] Intermediate 2c (9.46 g, crude product) and intermediate 1g (13.25 g, 55.7 mmol) were dissolved in ethanol (40 mL) in turn, and Py·HCl (0.66 g, 5.57 mmol) was added, and stirred at 80°C for 1.5 h. After the reaction was completed as monitored by TLC, the reaction solution was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 8: 1, v / v) to obtain intermediate 2d (15 g, yield 68%) as a brown foamy solid. 1 H NMR (300MHz, DMSO-d6) δ=7.34-7.29(m,1H),7.22(d,J=8.9Hz,1H),7.08(dd,J=6.9,2.5Hz,1H),5.22(br.s,2H),5.15-5.03(m,1H),4.21- 4.00(m,1H),3.10-2.98(m,1H),2.49(m,2H),2.13-2.05(m,1H),1.44(s,9H),1.26-1.24(m,3H),1.03-0.99(m,2H),0.79-0.77(m,2H)ppm. HR-MS(ESI + ): Calculated value C 21 H 27 FN4O2[M+H] + :387.2152, measured value 387.2152.

[0108] (3) Synthesis of intermediate 3e:

[0109]

[0110] Step 3-1:

[0111] CDI 3a (16.2 g, 100 mmol) was dissolved in ethyl acetate (150 mL), cooled to 5 °C, and 2,2-dimethoxyethylamine (10.5 g, 100 mmol) was slowly added dropwise, keeping the internal temperature below 10 °C. After the addition was completed, the mixture was moved to room temperature for 4 h. After the reaction was complete as monitored by TLC, the mixture was washed with water (100 mL × 3) and saturated brine (100 mL). The organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was slurried with isopropyl ether (50 mL), filtered and dried to obtain intermediate 3b (15.1 g, yield 76%) as a white solid. HR-MS (ESI + ): Calculated value for C8H 13 N3O3[M+H] + :200.0990, measured value 200.0978.

[0112] Step 3-2:

[0113] Intermediate 3b (5.0 g, 25.1 mmol) and intermediate 2d (6.47 g, 16.7 mmol) were dissolved in DMA (100 mL) in turn, and t-BuOK (4.37 g, 38.9 mmol) was added. The mixture was reacted at room temperature for 3 h. After the reaction was completed as monitored by TLC, the mixture was diluted with water (100 mL), extracted with ethyl acetate (50 mL×3), the organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 3:1, v / v) to obtain intermediate 3c (5.3 g, yield 62%). 1 H NMR (300MHz, DMSO-d6) δ = 7.23 (d, J = 6.4Hz, 2H), 5.20 (br.s, 2H), 5.12-5.01 (m, 1H), 4.16-4.02 (m, 1H), 3.07- 2.98(m,1H),2.46-2.42(m,2H),2.25(d,J=2.0Hz,6H),1.45(s,9H),1.05-0.99(m,2H),0.81-0.76(m,2H)ppm. HR-MS(ESI + ): Calculated value C 26 H 36 FN5O5[M+H] + :518.2734, measured value 518.2734.

[0114] Step 3-3:

[0115] The intermediate 3c (1.5 g, 3.9 mmol) was dissolved in THF (15 mL), and methanesulfonic acid (1.35 g, 11.6 mmol) was added. The reaction was carried out at 60 ° C for 3 h. After the reaction was completed by TLC monitoring, it was cooled to room temperature. The pH was adjusted to 9 with saturated K3PO4. (Boc)2O (6.86 g, 31.4 mmol) was added and stirred at room temperature for 2 h. Diluted with H2O (30 mL), extracted with ethyl acetate (20 mL×3), the organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 2:1, v / v) to obtain intermediate 3d (1.12 g, yield 85%), which was a light yellow foamy solid. HR-MS (ESI + ): Calculated value C 24 H 28 FN5O3[M+H] + :454.2210, measured value 454.2238.

[0116] Step 3-4:

[0117] The intermediate 3d (1.12 g, 2.47 mmol) was dissolved in DCM, and a hydrochloric acid dioxane solution (4N, 20 mL) was added and stirred at room temperature for 0.5 h. After the reaction was completed as monitored by TLC, the reaction solution was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 15: 1, v / v) to obtain the intermediate 3e (0.72 g, yield 83%) as a yellow solid. HR-MS (ESI + ): Calculated value C 27 H 25 F2N7O[M+H] + :354.1685, measured value 354.1612.

[0118] (4) Synthesis of intermediate 4d:

[0119]

[0120] Step 4-1:

[0121] Dissolve 4-chloro-2-pyridinecarboxaldehyde 4a (50 g, 353.2 mmol) in dioxane (500 mL) and water (500 mL), and add DABCO (39.6 g, 353.2 mmol) and methyl acrylate (91.2 g, 1059.7 mmol) in turn. Stir at room temperature for 0.5 h. After the reaction is complete as monitored by TLC, extract with ethyl acetate (300 mL×3), combine the organic phases, wash with saturated brine (500 mL), dry over anhydrous Na2SO4, and concentrate under reduced pressure to obtain an oily intermediate 4b (62 g, yield 77%). The crude product can be used in the next step without purification. HR-MS (ESI + ): Calculated value C 10 H 10 ClNO3[M+H] + :228.0349, measured value 228.0349.

[0122] Step 4-2:

[0123] The intermediate 4b (62g, 272mmol) was dissolved in acetic anhydride (1L) and stirred at 100°C for 1h under a nitrogen atmosphere. After the disappearance of the intermediate 4b monitored by TLC, the temperature was raised to reflux for 2h. After the reaction was completed by TLC monitoring, the reaction solution was cooled to room temperature, adjusted to pH≈9 with a saturated aqueous sodium carbonate solution, extracted with ethyl acetate (500mL×3), the organic phases were combined, washed with saturated brine (500mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was added with n-heptane (200mL) for slurrying, filtered, washed and dried to obtain the intermediate 4c (36g, yield 63%) as an off-white solid. 1 H NMR (300MHz, DMSO-d6) δ = 8.34-8.31 (d, J = 9.0Hz, 1H), 8.13 (m, 1H), 7.63 (m, 1H), 6.74 (s, 1H), 6.71 (dd, J = 7.5, 2.1Hz, 1H), 3.80 (s, 3H) ppm.

[0124] Step 4-3:

[0125] Intermediate 4c (36 g, 171.7 mmol) was dissolved in dioxane (360 mL), and diboric acid neopentyl glycol ester (58.2 g, 257.6 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) chloride (6.3 g, 8.59 mmol) and potassium propionate (38.5 g, 343.5 mmol) were added in sequence, and heated at 100°C for 2 h under nitrogen atmosphere. After the reaction was completed by TLC monitoring, water (300 mL) was added, and the aqueous phase was extracted with ethyl acetate (150 mL×3), and the organic phases were combined, washed with brine (200 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain intermediate 4d (35 g, yield 70%) as a yellow oil, which was used in the next step without purification.

[0126] (5) Synthesis of intermediate 5f:

[0127]

[0128] Step 5-1:

[0129] 2,2-Dimethyltetrahydropyran-4-one 5a (25 g, 195.05 mmol) was dissolved in THF (250 mL), cooled to -78 °C, and then LDA (2M, 117.03 mL) was slowly added dropwise, keeping the temperature below -75 °C. After stirring for 0.5 h, N-phenylbis(trifluoromethanesulfonyl)imide (76.65 g, 214.56 mmol) dissolved in THF (250 mL) was slowly added dropwise, keeping the temperature below -70 °C. Stirring was continued for 1 h, the temperature was raised to 25 °C, and stirring was continued for 8 h. After the reaction was complete as monitored by TLC, it was quenched with saturated NH4Cl aqueous solution (200 mL), extracted with ethyl acetate (200 mL×3), the organic phases were combined, washed with saturated brine (200 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain intermediate 5b as a light yellow oil (35 g, crude product), which was used in the next step without purification. HR-MS (ESI + ): Calculated value for C8H 11 F3O4S[M+H] + :261.0364, measured value 261.0364.

[0130] Step 5-2:

[0131] Intermediate 4d (25.7 g, 89.7 mmol) was dissolved in dioxane (250 mL) and water (50 mL), and intermediate 5b (35 g, 134.5 mmol), K2CO3 (37.2 g, 268.9 mmol), and Pd(dppf)Cl2 (6.6 g, 8.97 mmol) were added in sequence, and stirred at 110 ° C for 2 h under nitrogen atmosphere. After TLC monitoring, the reaction was completed, and the filtrate was filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 3: 1, v / v) to obtain intermediate 5c (20 g, yield 78%) as a white solid.

[0132] Step 5-3:

[0133] Intermediate 5c (20 g, 70.1 mmol) was dissolved in methanol (200 mL), and 10% Pd / C (4 g) was added, and stirred at room temperature for 8 h under a hydrogen atmosphere. After the reaction was completed by TLC monitoring, the mixture was filtered and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 3:1, v / v) to obtain intermediate 5d (18 g, yield 89%) as a white solid.

[0134] Step 5-4:

[0135] The intermediate 5d (5 g, 17.4 mmol) was dissolved in DMSO (50 mL) and H2O (10 mL), and bromoacetonitrile (2.2 g, 19.1 mmol), ferrous sulfate heptahydrate (2.3 g, 8.7 mmol), and NaI (2.49 g, 17.4 mmol) were added in sequence. After cooling to 0°C, 30% H2O2 (8.55 mL) was slowly added dropwise, and stirred at 0°C for 2 h. After the reaction was completed by TLC monitoring, it was quenched with water (50 mL), extracted with ethyl acetate (50 mL×3), and the organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 5:1, v / v) to obtain the intermediate 5e (4.2 g, yield 75%) as a light yellow solid. HR-MS (ESI + ): Calculated value C 19 H 22 N2O3[M+H] + :327.1664, measured value 327.1689.

[0136] Step 5-5:

[0137] Intermediate 5e (2 g, 6.12 mmol) was added to DMPU (20 mL), and then 1,3,2-dioxathiophene-2,2-dioxide (2.28 g, 18.4 mmol) was added, the temperature was lowered to 0°C, and LiHMDS (1 M, 26.8 mL) was slowly added dropwise, and stirred at 0°C for 2 h. After the reaction was completed by TLC monitoring, it was diluted with water (30 mL), extracted with ethyl acetate (30 mL×3), the organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 6:1, v / v) to obtain intermediate 5f (1.30 g, yield 60%) as a light yellow solid. HR-MS (ESI + ): Calculated value C 21 H 24 N2O3[M+H] + :353.1820, measured value 353.1888.

[0138] Step 5-6:

[0139] The intermediate 5f (1.30 g, 3.69 mmol) was dissolved in acetonitrile (10 mL), and then 1,5,7-triazabicyclo[4.4.0]dec-5-ene (2.06 g, 14.8 mmol) dissolved in water (2 mL) was added. Stir at room temperature for 2 h, and the pH was adjusted to 4 with 2N citric acid. A large amount of white solid precipitated, which was filtered, and the filter cake was washed with water and dried to obtain the intermediate 5g (1.0 g, yield 80%). HR-MS (ESI + ): Calculated value C 21 H 24 N2O3[M+H] + :339.1664, measured value 339.1666.

[0140] (6) Synthesis of intermediates 6a and 6b:

[0141]

[0142] Step 6-1:

[0143] Intermediate 5g (3g) was purified by SFC (chromatographic column: Daicel ChiralPak AD-H 250mm*30mm ID, 5pm; solvent: CO2 / IPA (0.1% DEA) = 65:35; detection wavelength: UV 254nm; column temperature: 40°C; flow rate: 50g / min) to obtain intermediate 6a (1.21g) and intermediate 6b (1.18g).

[0144] (7) Synthesis of intermediate 7c:

[0145]

[0146] Step 7-1:

[0147] Intermediate 6a (4.67 g, 13.8 mmol) was dissolved in DMF (50 mL), HATU (5.74 g, 15.1 mmol) and DIPEA (2.44 g, 18.9 mmol) were added in sequence, and the mixture was stirred at room temperature for 10 min, and then intermediate 3e (4.45 g, 12.6 mmol) was added, and the mixture was stirred at room temperature for 1 h. After the reaction was completed by TLC monitoring, the mixture was diluted with water (100 mL), extracted with dichloromethane (100 mL×3), the organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1, v / v) to obtain intermediate 7a (5.2 g, yield 61%) as a yellow solid.

[0148] Step 7-2:

[0149] The intermediate 7a (1.58 g, 2.34 mmol) was dissolved in ethanol (10 mL), and hydroxylamine hydrochloride (0.8 g, 11.7 mmol) and potassium carbonate (1.78 g, 12.9 mmol) were added in sequence, and the reaction was carried out at 80 ° C for 2 h. After the reaction was completed by TLC monitoring, it was concentrated under reduced pressure, H2O (30 mL) was added for slurrying, and the mixture was filtered, washed and dried. The filter cake was purified by silica gel column chromatography (dichloromethane: methanol = 30: 1, v / v) to obtain the intermediate 7b (1.27 g, yield 80%) as a light yellow solid. HR-MS (ESI + ): Calculated value C 27 H 32 N4O3[M+H] + :707.3425, measured value 707.3444.

[0150] Step 7-3:

[0151] The intermediate 7b (1.27 g, 1.80 mmol) was dissolved in DMSO (5 mL), and CDI (584 mg, 3.60 mmol) and DBU (686 mg, 4.5 mmol) were added in sequence, and the mixture was reacted at 25 °C for 0.5 h. After the reaction was completed by TLC monitoring, 1N HCl (20 mL) was added, and the mixture was filtered, washed, and dried. The filter cake was purified by silica gel column chromatography (dichloromethane: methanol = 40: 1, v / v) to obtain the intermediate 7c (0.90 g, yield 68%) as a light yellow solid. HR-MS (ESI + ): Calculated value C 28 H 30 N4O4[M+H] + :487.2301, measured value 487.2336.

[0152] Example 1: Synthesis of Compound 11a

[0153] (1) Synthesis of intermediate 8d:

[0154]

[0155] Step 1-1:

[0156] 2-Mercapto-5-bromofluorobenzene 8a (10.00 g, 48.30 mmol) was dissolved in DMSO (50 mL), and potassium tert-butoxide (8.55 g, 72.45 mmol) was added. The mixture was stirred at room temperature for 15 min, and then cyclopropane bromide (8.76 g, 72.45 mmol) was added. The mixture was stirred at 90°C for 48 h. After the reaction was completed as monitored by TLC, the mixture was diluted with water (100 mL), extracted with ethyl acetate (50 mL×3), and the organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain intermediate 8b as a light yellow oil (6 g, crude product), which was used in the next step without purification.

[0157] Step 1-2:

[0158] To intermediate 8b (6 g, 24.3 mmol) was added anhydrous ethanol (60 mL), followed by the addition of PhI(OAc)2 (23.46 g, 72.84 mmol) and CH3COONH4 (7.49 g, 97.11 mmol), and the mixture was stirred at room temperature for 5 h. After the reaction was completed by TLC monitoring, the ethanol was concentrated under reduced pressure, diluted with water (100 mL), and extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether:ethyl acetate=2:1, v / v) to give intermediate 8c (3.1 g, yield 46%) as a light yellow oil.

[0159] Steps 1-3:

[0160] Intermediate 8c (3.1 g, 11.15 mmol) was dissolved in DMF (20 mL), and methylamine hydrochloride (1.13 g, 16.71 mmol) and potassium carbonate (3.08 g, 22.29 mmol) were added in sequence. The mixture was stirred at room temperature for 1 h, diluted with water (50 mL), and extracted with ethyl acetate (20 mL×3). The organic phases were combined, washed with saturated brine (40 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 2:1, v / v) to give intermediate 8d (2.9 g, yield 90%) as a light yellow oil.

[0161] (2) Synthesis of intermediates 9a and 9b:

[0162]

[0163] Step 2-1:

[0164] Intermediate 8d (300 mg) was purified by HPLC (chromatographic column: Daicel CHIRALPAK IH 2.5 cm ID × 25 cm L, 5 μm; solvent: n-Hexane / EtOH = 65:35; detection wavelength: UV 210 nm; column temperature: 40 ° C; flow rate: 40 mL / min) to give intermediate 9a (121 mg, R t =8.55min) and intermediate 9b (118 mg, R t =10.68min).

[0165] (3) Synthesis of compound 11a:

[0166]

[0167] Step 3-1:

[0168] Intermediate 7c (100 mg, 0.136 mmol) was dissolved in NMP (5 mL), and intermediate 9a (39.5 mg, 0.164 mmol), (1S, 2S)-N, N'-dimethyl-1,2-cyclohexanediamine (7.7 mg, 0.056 mmol), potassium carbonate (377 mg, 0.273 mmol), and copper (I) iodide (8 mg, 0.028 mmol) were added in sequence. Stir at 130 ° C for 3 h under nitrogen atmosphere. After TLC monitoring, the reaction was completed, quenched with water (5 mL), extracted with ethyl acetate (5 mL×3), and the organic phases were combined, washed with saturated brine (5 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1, v / v) to obtain compound 11a (25 mg, yield 19%) as a yellow solid. 1H NMR (300MHz, CDCl3) δ = 11.54, (s, 1H), 8.17 (d, J = 3.6Hz, 1H), 7.79 (d, J = 4.1Hz, 1H), 7.26-7.18 (m, 2H), 7.06(t,J=9.3Hz,1H),7.00-6.98(m,2H),6.82-6.79(m,2H),6.64(d,J=4.5Hz,1H),6.38-6.35(m,2H),3 .87-3.83(m,3H),3.16-3.06(s,2H),2.94(s,3H),2.91-2.79(m,2H),2.15-2.06(m,4H),1.52-1.49(m,5 H),1.42-1.39(m,2H),1.35-1.27(m,12H),1.02-0.95(m,2H),0.92-0.87(m,2H),0.70-0.64(m,2H)ppm. HR-MS(ESI + ): Calculated value C 50 H 53 FN 10 O6S[M+H] + :941.3888, measured value 941.3869.

[0169] Example 2: Synthesis of Compound 11b

[0170]

[0171] Step 1-1:

[0172] Intermediate 7c (100 mg, 0.136 mmol) was dissolved in NMP (5 mL), and intermediate 9b (39.5 mg, 0.164 mmol), (1S, 2S)-N, N'-dimethyl-1,2-cyclohexanediamine (7.7 mg, 0.056 mmol), potassium carbonate (377 mg, 0.273 mmol), and copper (I) iodide (8 mg, 0.028 mmol) were added in sequence. Stir at 130 ° C for 3 h under nitrogen atmosphere. After TLC monitoring, the reaction was completed, quenched with water (5 mL), extracted with ethyl acetate (5 mL×3), and the organic phases were combined, washed with saturated brine (5 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1, v / v) to obtain compound 11b (31 mg, yield 24%) as a yellow solid. 1H NMR (300MHz, CDCl3) δ = 11.54, (s, 1H), 8.18 (d, J = 3.6Hz, 1H), 7.79 (d, J = 4.1Hz, 1H), 7.26-7.18 (m, 2H), 7.06(t,J=9.3Hz,1H),7.01-6.99(m,2H),6.82-6.79(m,2H),6.64(d,J=4.5Hz,1H),6.38-6.35(m,2H),3 .88-3.84(m,3H),3.16-3.06(s,2H),2.94(s,3H),2.91-2.79(m,2H),2.15-2.06(m,4H),1.52-1.49(m,5 H),1.42-1.39(m,2H),1.35-1.27(m,12H),1.02-0.95(m,2H),0.92-0.87(m,2H),0.70-0.64(m,2H)ppm. HR-MS(ESI + ): Calculated value C 50 H 53 FN 10 O6S[M+H] + :941.3888, measured value 941.3869.

[0173] Example 3: Synthesis of Compound 12a

[0174] (1) Synthesis of intermediates 10a and 10b:

[0175]

[0176] Step 1-1:

[0177] Intermediate 8c (300 mg) was purified by HPLC (chromatographic column: Daicel CHIRALPAK IH 2.5 cm ID×25 cm L, 5 μm; solvent: n-Hexane / EtOH=65:35; detection wavelength: UV 210 nm; column temperature: 40°C; flow rate: 40 mL / min) to give intermediate 10a (115 mg, R t =6.70 min) and intermediate 10b (132 mg, R t =7.47min).

[0178] (2) Synthesis of compound 12a:

[0179]

[0180] Step 2-1:

[0181] Intermediate 7c (100 mg, 0.136 mmol) was dissolved in NMP (5 mL), and intermediate 10a (45.5 mg, 0.164 mmol), (1S, 2S)-N, N'-dimethyl-1,2-cyclohexanediamine (7.7 mg, 0.78 g, 0.056 mmol), potassium carbonate (377 mg, 0.273 mmol), and copper (I) iodide (8 mg, 0.028 mmol) were added in sequence. Stir at 130 ° C for 3 h under nitrogen atmosphere. After TLC monitoring, the reaction was completed, quenched with water (5 mL), extracted with ethyl acetate (5 mL×3), and the organic phases were combined, washed with saturated brine (5 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1, v / v) to obtain compound 12a (30 mg, yield 24%) as a yellow solid. 1 H NMR (300MHz, CDCl3) δ = 11.54, (s, 1H), 8.17 (d, J = 3.3Hz, 1H), 8.05 (t, J = 8.0Hz, 1H), 7.79 (d, J = 5.6Hz, 1H) ,7.52(d,J=4.4Hz,1H),7.26-7.18(m,2H),7.06(t,J=9.3Hz,1H),7.00-6.97(m,1H),6.84-6.83(m,1H),6. 66-6.63(m,1H),6.42-6.38(m,2H),3.87-3.83(m,3H),3.16-2.87(m,4H),2.15-2.06(m,4H),1.52-1.49(m ,5H),1.52-1.49(m,2H),1.35-1.27(m,12H),1.02-0.95(m,2H),0.92-0.87(m,2H),0.70-0.64(m,2H)ppm. HR-MS(ESI + ): Calculated value C 49 H 49 F2N9O6S[M+H] + :930.3528, measured value 930.3544.

[0182] Example 4: Synthesis of Compound 12b:

[0183]

[0184] Step 1-1:

[0185] Intermediate 7c (100 mg, 0.136 mmol) was dissolved in NMP (5 mL), and intermediate 10b (45.5 mg, 0.164 mmol), (1S, 2S)-N, N'-dimethyl-1,2-cyclohexanediamine (7.7 mg, 0.056 mmol), potassium carbonate (377 mg, 0.273 mmol), and copper (I) iodide (8 mg, 0.028 mmol) were added in sequence. Stir at 130 ° C for 3 h under nitrogen atmosphere. After TLC monitoring, the reaction was completed, quenched with water (5 mL), extracted with ethyl acetate (5 mL×3), and the organic phases were combined, washed with saturated brine (5 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1, v / v) to obtain compound 12b (28 mg, yield 22%) as a yellow solid. 1 H NMR (300MHz, CDCl3) δ = 11.54, (s, 1H), 8.18 (d, J = 3.3Hz, 1H), 8.05 (t, J = 8.0Hz, 1H), 7.79 (d, J = 5.6Hz, 1H) ,7.52(d,J=4.4Hz,1H),7.25-7.17(m,2H),7.06(t,J=9.3Hz,1H),7.00-6.97(m,1H),6.84-6.83(m,1H),6. 66-6.63(m,1H),6.42-6.38(m,2H),3.87-3.83(m,3H),3.16-2.87(m,4H),2.13-2.08(m,4H),1.52-1.49(m ,5H),1.52-1.49(m,2H),1.35-1.27(m,12H),1.02-0.95(m,2H),0.92-0.87(m,2H),0.70-0.64(m,2H)ppm. HR-MS(ESI + ): Calculated value C 49 H 49 F2N9O6S[M+H] + :930.3528, measured value 930.3544.

[0186] Example 5: Synthesis of Compound 15

[0187] (1) Synthesis of intermediate 11b:

[0188]

[0189] Step 1-1:

[0190] The intermediate 8c (1g, 3.59mmol) was dissolved in 1,4-dioxane (15mL), and copper acetate (1.07g, 5.39mmol) and pyridine (680mg, 8.63mmol) were added in sequence. The mixture was stirred at 25°C for 0.5h, and then methylboric acid (430mg, 7.20mmol) was added. After nitrogen substitution, the mixture was reacted at 100°C for 2h. After the reaction was completed as monitored by TLC, the reaction solution was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 2:1, v / v) to obtain the intermediate 11a (700mg, yield 62%). HR-MS (ESI + ): Calculated value C 10 H 11 BrFNOS[M+H] + :291.9729, measured value 291.9777.

[0191] Step 1-2:

[0192] The intermediate 11a (700 mg, 2.40 mmol) was dissolved in DMF (10 mL), and methylamine hydrochloride (243 mg, 3.59 mmol) and potassium carbonate (993 mg, 7.19 mmol) were added in sequence, stirred at room temperature for 1 h, diluted with water (50 mL), extracted with ethyl acetate (20 mL×3), the organic phases were combined, washed with saturated brine (40 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 2:1, v / v) to obtain the intermediate 11b (620 mg, yield 85%) as a light yellow oil. HR-MS (ESI + ): Calculated value C 11 H 15 BrN2OS[M+H] + :303.2180, measured value 303.2108.

[0193] (2) Synthesis of compound 15:

[0194]

[0195] Step 2-1:

[0196] Intermediate 7c (100 mg, 0.136 mmol) was dissolved in NMP (5 mL), and intermediate 11b (49.7 mg, 0.164 mmol), (1S, 2S)-N, N'-dimethyl-1,2-cyclohexanediamine (7.7 mg, 0.056 mmol), potassium carbonate (377 mg, 0.273 mmol), and copper (I) iodide (8 mg, 0.028 mmol) were added in sequence. Stir at 130 ° C for 3 h under nitrogen atmosphere. After TLC monitoring, the reaction was completed, quenched with water (5 mL), extracted with ethyl acetate (5 mL×3), and the organic phases were combined, washed with saturated brine (5 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1, v / v) to obtain compound 15 (23 mg, yield 17%) as a yellow solid. 1 H NMR (300MHz, CDCl3) δ = 11.54, (s, 1H), 8.18 (d, J = 3.6Hz, 1H), 7.79 (d, J = 4.1Hz, 1H), 7.26-7.18 (m, 2H), 7.0 6(t,J=9.3Hz,1H),7.01-6.99(m,2H),6.82-6.79(m,2H),6.64(d,J=4.5Hz,1H),6.38-6.35(m,2H),3.88-3. 84(m,3H),3.16-3.06(s,2H),2.94(s,3H),2.91-2.79(m,2H),2.66(s,3H),2.15-2.06(m,4H),1.52-1.49(m ,4H),1.42-1.39(m,2H),1.35-1.27(m,12H),1.02-0.95(m,2H),0.92-0.87(m,2H),0.70-0.64(m,2H)ppm. HR-MS(ESI + ): Calculated value C 51 H 55 FN 10 O6S[M+H] + :955.4044, measured value 955.4021.

[0197] Example 6: Synthesis of Compound 17

[0198] (1) Synthesis of intermediate 12b:

[0199]

[0200] Step 1-1:

[0201] The intermediate 8c (2 g, 7.19 mmol) was dissolved in dichloromethane (5 mL), DMAP (0.97 g, 7.91 mmol) was added, and then cyanogen bromide (1.52 g, 14.38 mmol) was added. After stirring at room temperature for 10 min, the mixture was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1, v / v) to obtain the intermediate 12a (1.5 g, yield 69%) as a light yellow oil. HR-MS (ESI + ): Calculated value C 10 H8BrFN2OS[M+H] + :302.9525, measured value 302.9566.

[0202] Step 1-2:

[0203] The intermediate 12a (1.5 g, 4.94 mmol) was dissolved in DMF (15 mL), and methylamine hydrochloride (0.67 g, 9.90 mmol) and potassium carbonate (2.05 g, 14.84 mmol) were added in sequence, stirred at room temperature for 1 h, diluted with water (50 mL), extracted with ethyl acetate (20 mL×3), the organic phases were combined, washed with saturated brine (40 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1, v / v) to obtain the intermediate 12b (1.2 g, yield 77%) as a light yellow oil. HR-MS (ESI + ): Calculated value C 11 H 12 BrN3OS[M+H] + :313.9884, measured value 313.9895.

[0204] (2) Synthesis of compound 17:

[0205]

[0206] Step 2-1:

[0207] Intermediate 7c (100 mg, 0.136 mmol) was dissolved in NMP (5 mL), and intermediate 12b (51.5 mg, 0.164 mmol), (1S, 2S)-N, N'-dimethyl-1,2-cyclohexanediamine (7.7 mg, 0.056 mmol), potassium carbonate (377 mg, 0.273 mmol), and copper (I) iodide (8 mg, 0.028 mmol) were added in sequence. Stir at 130 ° C for 3 h under nitrogen atmosphere. After TLC monitoring, the reaction was completed, quenched with water (5 mL), extracted with ethyl acetate (5 mL×3), and the organic phases were combined, washed with saturated brine (5 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1, v / v) to obtain compound 17 (32 mg, yield 25%) as a yellow solid. 1 H NMR (300MHz, CDCl3) δ = 11.54, (s, 1H), 8.17 (d, J = 3.6Hz, 1H), 7.79 (d, J = 4.1Hz, 1H), 7.26-7.18 (m, 2 H),7.10-7.00(m,3H),6.82-6.79(m,2H),6.64(d,J=4.5Hz,1H),6.38-6.35(m,2H),3.87-3.83(m,3 H),2.98-2.90(m,5H),2.86-2.75(m,2H),2.15-2.06(m,4H),1.55-1.53(m,2H),1.42-1.40(m,2H), 1.40-1.38(m,2H),1.35-1.27(m,12H),1.02-0.95(m,2H),0.92-0.87(m,2H),0.70-0.64(m,2H)ppm. HR-MS(ESI + ): Calculated value C 51 H 52 FN 11 O6S[M+H] + :966.3840, measured value 966.3854.

[0208] Example 7: Synthesis of Compound 29

[0209] (1) Synthesis of intermediate 13e:

[0210]

[0211] Step 1-1:

[0212] 2-Fluoro-4-bromobenzyl bromide 13a (5.00 g, 18.67 mmol) was dissolved in DMF (50 mL), and sodium thiomethoxide (3.90 g, 56.0 mmol) was added. The mixture was stirred at room temperature for 30 min. After the reaction was completed as monitored by TLC, it was diluted with water (100 mL), extracted with ethyl acetate (50 mL×3), and the organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain intermediate 13b as a colorless oil (3.8 g, 86%), which was used in the next step without purification.

[0213] Step 1-2:

[0214] Intermediate 13b (3.80 g, 16.16 mmol) was dissolved in water (30 mL), EtOAc (60 mL) and MeOH (30 mL), then NaIO4 (3.46 g, 16.16 mmol) was added and stirred at 20°C for 4 h. After the reaction was completed by TLC monitoring, it was extracted with DCM (50 mL×3), the organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain intermediate 13c as a light yellow oil (3.15 g, 78%), which was used in the next step without purification.

[0215] Steps 1-3:

[0216] Intermediate 13c (3.15 g, 12.6 mmol) was dissolved in DCM (30 mL), and magnesium oxide (2.02 g, 50.17 mmol), iodobenzene diacetate (6.06 g, 18.8 mmol), dimerized rhodium acetate (0.14 g, 0.31 mmol) and 2,2,2-trifluoroacetamide (2.84 g, 25.1 mmol) were added in sequence. The mixture was stirred at 25 °C for 10 h. After the reaction was completed under TLC monitoring, the mixture was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1, v / v) to give intermediate 13d (2.50 g, yield 55%) as a yellow solid. HR-MS (ESI + ): Calculated value C 10 H8BrF4NO2S[M+H] + :361.9395, measured value 361.9411.

[0217] Steps 1-4:

[0218] The intermediate 13d (2.50 g, 6.90 mmol) was dissolved in 2-methylTHF (50 mL), and then 1,2-dibromoethane (5.19 g, 27.6 mmol), tetraoctylammonium bromide (0.38 g, 0.69 mmol) and aqueous sodium hydroxide solution (50% w / w) (22.1 mL, 414.2 mmol) were added in sequence, stirred at 60°C for 24 h, then quenched with water (50 mL), extracted with ethyl acetate (50 mL×3), the organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1, v / v) to obtain the intermediate 13e (1.05 g, yield 52%) as a yellow solid. HR-MS (ESI + ): Calculated value C 10 H 11 BrFNOS[M+H] + :291.9729, measured value 291.9711.

[0219] Steps 1-5:

[0220] The intermediate 13e (1.05 g, 4.00 mmol) was dissolved in DMF (10 mL), and methylamine hydrochloride (405 mg, 6.00 mmol) and potassium carbonate (1.11 g, 8.00 mmol) were added in sequence, stirred at room temperature for 1 h, diluted with water (40 mL), extracted with ethyl acetate (20 mL×3), the organic phases were combined, washed with saturated brine (40 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 2:1, v / v) to obtain the intermediate 13f (800 mg, yield 66%) as a light yellow oil. HR-MS (ESI + ): Calculated value C 11 H 15 BrN2OS[M+H] + :303.0088, measured value 303.0111.

[0221] (2) Synthesis of compound 29:

[0222]

[0223] Step 2-1:

[0224] Intermediate 7c (100 mg, 0.136 mmol) was dissolved in NMP (5 mL), and intermediate 13e (49.7 mg, 0.164 mmol), (1S, 2S)-N, N'-dimethyl-1,2-cyclohexanediamine (7.7 mg, 0.056 mmol), potassium carbonate (377 mg, 0.273 mmol), and copper (I) iodide (8 mg, 0.028 mmol) were added in sequence. The mixture was stirred at 130 ° C for 3 h under a nitrogen atmosphere. After the reaction was completed by TLC monitoring, it was quenched with water (5 mL), extracted with ethyl acetate (5 mL×3), and the organic phases were combined, washed with saturated brine (5 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1, v / v) to obtain compound 29 (32 mg, yield 25%) as a yellow solid. 1 H NMR (300MHz, CDCl3) δ = 11.54, (s, 1H), 8.17 (d, J = 3.8Hz, 1H), 7.79 (d, J = 4.2Hz, 1H), 7.26-7.18 (m, 2H), 7.10-7.00(m,3H),6.82-6.79(m,2H),6.64(d,J=4.3Hz,1H),6.38-6.35(m,2H),3.87-3.83(m,3H),2.9 8-2.90(m,5H),2.86-2.75(m,2H),2.53(s,3H),2.23-2.17(m,2H),2.16-2.13(m,2H),1.52-1.49(m,4H ),1.42-1.39(m,2H),1.35-1.27(m,12H),1.02-0.95(m,2H),0.90-0.85(m,2H),0.71-0.65(m,2H)ppm. HR-MS(ESI + ): Calculated value C 51 H 55 FN 10 O6S[M+H] + :955.4044, measured value 955.4044.

[0225] Example 8: Synthesis of Compound 39

[0226] (1) Synthesis of intermediate 14a:

[0227]

[0228] Step 1-1:

[0229] Intermediate 13e (1.0 g, 3.98 mmol) was dissolved in toluene (10 mL) and methanol (2 mL), and PhI(OAc)2 (2.57 g, 7.96 mmol) and NH2COONH4 (1.24 g, 15.93 mmol) were added in sequence at 0°C, and stirred at 10°C for 5 h. After the reaction was completed by TLC monitoring, toluene was concentrated under reduced pressure, diluted with water (50 mL), extracted with ethyl acetate (50 mL×3), and the organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1, v / v) to give intermediate 14a (0.72 g, yield 68%) as a light yellow oil.

[0230] (2) Synthesis of compound 39:

[0231]

[0232] Step 2-1:

[0233] Intermediate 7c (100 mg, 0.136 mmol) was dissolved in NMP (5 mL), and intermediate 14a (43.6 mg, 0.164 mmol), (1S, 2S)-N, N'-dimethyl-1,2-cyclohexanediamine (7.7 mg, 0.056 mmol), potassium carbonate (377 mg, 0.273 mmol), and copper (I) iodide (8 mg, 0.028 mmol) were added in sequence. The mixture was stirred at 130 ° C for 3 h under a nitrogen atmosphere. After the reaction was completed by TLC monitoring, it was quenched with water (5 mL), extracted with ethyl acetate (5 mL×3), and the organic phases were combined, washed with saturated brine (5 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1, v / v) to obtain compound 39 (25 mg, yield 20%) as a yellow solid. 1H NMR (300MHz, CDCl3) δ = 11.54, (s, 1H), 8.17 (d, J = 3.3Hz, 1H), 8.05 (t, J = 8.0Hz, 1H), 7.79 (d, J = 5.6Hz, 1H), 7.52 (d, J = 4. 4Hz,1H),7.26-7.18(m,2H),7.06(t,J=9.3Hz,1H),7.00-6.97(m,1H),6.84-6.83(m,1H),6.66-6.63(m,1H),6.42-6.38( m,2H),4.12(m,1H),4.07(m,1H),3.87-3.83(m,3H),3.16-3.08(m,1H),2.99-2.93(m,2H),2.50(s,3H),2.15-2.06(m,4H ),1.52-1.49(m,5H),1.52-1.49(m,2H),1.35-1.27(m,8H),1.02-0.95(m,2H),0.92-0.87(m,2H),0.70-0.64(m,2H)ppm. HR-MS(ESI + ): Calculated value C 48 H 49 F2N9O6S[M+H] + :918.3528, measured value 918.3532.

[0234] Example 9: Synthesis of Compound 49a

[0235] (1) Synthesis of intermediate 151:

[0236]

[0237] Step 1-1:

[0238] 5-Bromo-1H-indole-2-carboxylic acid 15a (12.2 g, 50.61 mmol) was dissolved in acetonitrile (100 mL), and DMF (1.95 mL, 25.3 mmol) was added. Oxalyl chloride (8.35 g, 65.79 mmol) dissolved in acetonitrile (10 mL) was slowly added dropwise, and stirred for 1 h. The reaction solution was cooled to 5 ° C. TEA (17 mL, 121.5 mmol) and N-methylaniline (6.5 g, 60.73 mmol) were added in sequence, stirred at room temperature for 2 h, and quenched with water (10 mL). Filtered with suction, the filter cake was washed with water (50 mL). Drying gave intermediate 15b (13.0 g, yield 78%).

[0239] Step 1-2:

[0240] Intermediate 15b (13.0 g, 39.5 mmol) was dissolved in DMA (130 mL). Tri-tert-butylphosphine tetrafluoroborate (114 g, 395 mmol), N-methyldicyclohexylamine (30.9 g, 158 mmol), acrylic acid (4.27 g, 59.25 mmol), allylpalladium (II) chloride dimer (365 mg, 1 mmol) were added in sequence, and the mixture was stirred at 70 ° C for 18 h after nitrogen replacement. After the reaction was completed by TLC detection, the pH was adjusted to 3 with 1M H2SO4 aqueous solution, water (50 mL) was added, and the mixture was stirred for 1 h, filtered, washed and dried to obtain intermediate 15c (10.0 g, yield 79%). HR-MS (ESI + ): Calculated value C 19 H 16 N2O3[M+H] + :321.1194, measured value 321.1211.

[0241] Steps 1-3:

[0242] The intermediate 15c (10.0 g, 31.2 mmol) was dissolved in acetonitrile (100 mL). CDI (6.08 g, 37.5 mmol) was added, and the mixture was reacted at 10°C for 2 h. The mixture was filtered with suction, and the filter cake was dissolved in DMA (100 mL). (R)-4-benzyl-2-oxazolidinone (6.65 g, 37.5 mmol) and DBU (1.9 g, 78.0 mmol) were added in sequence. The mixture was stirred at 20°C for 1 h, and then the pH was adjusted to 4 with 5N HCl. The mixture was filtered with suction, and the filter cake was washed and dried to obtain the intermediate 15d (12.0 g, 80.2%). HR-MS (ESI + ): Calculated value C 29 H 25 N3O4[M+H] + :480.1879, measured value 480.1888.

[0243] Steps 1-4:

[0244] Lithium chloride (3.71 g, 87.6 mol) was dissolved in THF (100 mL), and 2-methylallyl magnesium chloride (0.5 M, THF solution) (172.6 mL) was added. The mixture was cooled to -40 ° C, and CuI (16.7 g, 87.6 mol) was added, and intermediate 15d (12.0 g, 25.0 mol) dissolved in THF (50 mL) was added dropwise. The temperature was kept not higher than -30 ° C, stirred at -40 ° C for 8 h, and then quenched with 10% aqueous ammonium chloride solution (100 mL). It was extracted with MTBE (80 mL × 3), the organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 60: 1, v / v) to obtain intermediate 15e (9.5 g, yield 71%). 1 H NMR (300MHz, DMSO-d6) δ = 11.46 (s, 1H), 7.22-7.48 (m, 9H), 7.10-7.15 (m, 3H), 7.05 (d, 7 = 8.53Hz, 1H), 5.17 (s, 1H), 4.58 (br d,J=16.56Hz,2H),4.42-4.48(m,1H),4.05-4.14(m,2H),3.35-3.45(m,4H) ,2.99-3.19(m,2H),2.74-2.89(m.2H),2.25-2.42(m,2H),1.61(s,3H)ppm. HR-MS(ESI + ): Calculated value C 33 H 33 N3O4[M+H] + :536.2505, measured value 536.2572.

[0245] Steps 1-5:

[0246] Intermediate 15e (9.5 g, 17.7 mmol) was dissolved in THF (100 mL), and glacial acetic acid (10 mL), H2O (30 mL) and EtOH (20 mL) were added in sequence. The mixture was cooled to -20 °C, and lithium borohydride solution (2M in THF solution) (9 mL, 18 mmol) was slowly added dropwise, and then stirred at 10 °C for 15 h. After the reaction was completed by TLC monitoring, it was quenched with saturated aqueous ammonium chloride solution (50 mL). It was extracted with MTBE (50 mL×3), the organic phases were combined, washed with H2O (50 mL) and saturated brine (50 mL) in sequence, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain intermediate 15f (8.5 g, crude product), which was used in the next step without purification. HR-MS (ESI + ): Calculated value C 23 H 26N2O2[M+H] + :363.2028, measured value 363.2091.

[0247] Steps 1-6:

[0248] The intermediate 15f (8.5 g, 23.5 mol) was dissolved in cyclopentyl methyl ether (60 mL), and p-toluenesulfonic acid monohydrate (11.1 g, 58.6 mol) was added, and heated at 60°C for 12 h. After the reaction was completed by TLC detection, it was quenched with 1N sodium hydroxide aqueous solution (80 mL), and then isopropanol (10 mL) and n-heptane (85 mL) were added in sequence, cooled to room temperature, filtered, and the filter cake was washed with isopropanol (10 mL). The intermediate 15g (7.05 g, yield 83%) was obtained by drying as a light yellow solid. HR-MS (ESI + ): Calculated value C 23 H 26 N2O2[M+H] + :363.2028, measured value 363.2090.

[0249] Steps 1-7:

[0250] Intermediate 15g (7.05g, 19.5mmol) was dissolved in toluene (70mL), and the mixture was heated at 50°C for 2h and cooled to room temperature. Potassium hydroxide (50% w / w) (4.39g, 78mmol) and tetrabutylammonium chloride hydrate (0.57g, 1.95mmol) were added in sequence and the mixture was cooled to 0°C. Chloroacetonitrile (1.91g, 25.3mmol) dissolved in toluene (10mL) was slowly added dropwise and stirred for 2h. After the TLC reaction was completed, the liquids were separated, and the organic layer was washed with 5% aqueous sodium bicarbonate solution (50mL×5). MTBE (10mL) and n-heptane (100mL) were added to the organic layer, and the mixture was stirred at room temperature for 0.5h and then filtered. The intermediate 15h (6.50g, yield 83%) was obtained by washing and drying. HR-MS (ESI + ): Calculated value C 25 H 27 N3O2[M+H] + :402.2137, measured value 402.2187.

[0251] Steps 1-8:

[0252] Intermediate 15h (6.50 g, 16.2 mmol) was dissolved in THF (60 mL) at 0°C, and (R)-4-methyl-1,3,2-dioxathiolane 2,2-dioxide (4.65 g, 33.1 mmol) was added. Lithium tert-butoxide (2N in THF) (65 mL, 129 mmol) was slowly added and stirred for 20 h. After the reaction was completed by TLC monitoring, the mixture was quenched with 50% aqueous acetic acid (20 mL) and diluted with n-heptane (50 mL). The liquids were separated and the organic layer was washed with water (2×50 mL). Drying over anhydrous Na2SO4 and concentration under reduced pressure were performed. The crude product was recrystallized using acetonitrile (40 mL) and water (30 mL). Filtration, washing and drying gave intermediate 15i (5.8 g, yield 83%). HR-MS (ESI + ): Calculated value C 28 H 34 N2O2[M+H] + :442.2450, measured value 442.2487.

[0253] Steps 1-9:

[0254] The intermediate 15i (5.8 g, 13.5 mmol) was dissolved in ethanol (10 mL), and hydroxylamine hydrochloride (0.47 g, 68117 mmol) and potassium carbonate (1.02 g, 7.4 mmol) were added in sequence, and the reaction was carried out at 80 ° C for 2 h. After the reaction was completed by TLC monitoring, it was concentrated under reduced pressure, H2O (20 mL) was added for slurrying, and the mixture was filtered, washed and dried. The filter cake was purified by silica gel column chromatography (dichloromethane: methanol = 30: 1, v / v) to obtain the intermediate 15j (5.3 g, yield 83%) as a light yellow solid. HR-MS (ESI + ): Calculated value C 28 H 34 N4O3[M+H] + :475.2664, measured value 475.2666.

[0255] Steps 1-10:

[0256] The intermediate 15j (5.30 g, 11.1 mmol) was dissolved in DMSO (5 mL), and CDI (3.6 g, 22.2 mmol) and DBU (4.3 g, 28 mmol) were added in sequence, and the mixture was reacted at 25 °C for 0.5 h. After the reaction was completed by TLC monitoring, 1N HCl (40 mL) was added, and the mixture was filtered, washed, and dried. The filter cake was purified by silica gel column chromatography (dichloromethane: methanol = 40: 1, v / v) to obtain the intermediate 15k (5.0 g, yield 89%) as a light yellow solid. HR-MS (ESI + ): Calculated value C 29 H 32 N4O4[M+H]+ :501.2457, measured value 501.2421.

[0257] Steps 1-11:

[0258] Dissolve the intermediate 15k (5.0 g, 10 mol) in 1,3-dimethyl-2-imidazolidinone (50 mL), and then add water (0.25 mL, 0.025 mol) and sodium tert-butoxide (2.9 g, 30 mol). Slowly heat to 80 ° C and stir for 10 h. After TLC monitoring of the reaction is complete, the reaction mixture is cooled to 10 ° C. Adjust the pH to 5 with 6M HCl under ice bath, add water (50 mL) to dilute, and extract with ethyl acetate (30 mL × 3). Combine the organic phases, wash with saturated brine (30 mL), dry over anhydrous Na2SO4, and concentrate under reduced pressure to obtain intermediate 15l (3.2 g, yield 77%). The crude product can be used in the next step without purification. HR-MS (ESI + ): Calculated value C 22 H 25 N3O5[M+H] + :412.1828, measured value 412.1865.

[0259] (2) Synthesis of intermediate 16a:

[0260]

[0261] Step 2-1:

[0262] Intermediate 15l (518.4 mg, 1.26 mmol) was dissolved in DMF (5 mL), and HATU (574 mg, 1.51 mmol) and DIPEA (244 mg, 1.89 mmol) were added in sequence, and stirred at room temperature for 10 min, and then intermediate 3e (487 mg, 1.38 mmol) was added, and stirred at room temperature for 1 h. After the reaction was completed by TLC monitoring, it was diluted with water (10 mL), extracted with dichloromethane (10 mL×3), and the organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1, v / v) to obtain intermediate 16a (650 mg, yield 67%) as a yellow solid. HR-MS (ESI + ): Calculated value C 41 H 43 FN8O5[M+H] + :747.3374, measured value 747.3345.

[0263] (3) Synthesis of Compound 49a

[0264]

[0265] Step 3-1:

[0266] Intermediate 16a (101 mg, 0.136 mmol) was dissolved in NMP (5 mL), and intermediate 9a (39.5 mg, 0.164 mmol), (1S, 2S)-N, N'-dimethyl-1,2-cyclohexanediamine (7.7 mg, 0.056 mmol), potassium carbonate (377 mg, 0.273 mmol), and copper (I) iodide (8 mg, 0.028 mmol) were added in sequence. Stir at 130 ° C for 3 h under nitrogen atmosphere. After TLC monitoring, the reaction was completed, quenched with water (5 mL), extracted with ethyl acetate (5 mL×3), and the organic phases were combined, washed with saturated brine (5 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1, v / v) to obtain compound 49a (33 mg, yield 25%) as a yellow solid. 1 H NMR(300MHz, CDCl3)=8.31(s,1H),7.63(d,J=8.9Hz,1H),7.57-7.23(m,2H),7.20(m,2H),7.09( m,1H),6.82-6.79(m,2H),6.64(d,J=4.5Hz,1H),6.38-6.35(m,2H),3.87-3.83(m,3H),3.20-3.1 6(s,2H),2.94(s,3H),2.91-2.79(m,2H),2.15-2.06(m,4H),1.52-1.49(m,5H),1.42-1.39(m,2H ),1.35-1.29(m,12H),1.28(s.3H),1.02-0.95(m,2H),0.92-0.87(m,2H),0.70-0.64(m,2H)ppm. HR-MS(ESI + ): Calculated value C 51 H 55 FN 10 O6S[M+H] + :955.4044, measured value 955.4023.

[0267] Example 10: Synthesis of Compound 49b

[0268]

[0269] Step 1-1:

[0270] Intermediate 16a (101 mg, 0.136 mmol) was dissolved in NMP (5 mL), and intermediate 9b (39.5 mg, 0.164 mmol), (1S, 2S)-N, N'-dimethyl-1,2-cyclohexanediamine (7.7 mg, 0.056 mmol), potassium carbonate (377 mg, 0.273 mmol), and copper (I) iodide (8 mg, 0.028 mmol) were added in sequence. Stir at 130 ° C for 3 h under nitrogen atmosphere. After TLC monitoring, the reaction was completed, quenched with water (5 mL), extracted with ethyl acetate (5 mL×3), and the organic phases were combined, washed with saturated brine (5 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1, v / v) to obtain compound 49b (35 mg, yield 27%) as a yellow solid. 1 H NMR(300MHz, CDCl3)=8.31(s,1H),7.63(d,J=8.9Hz,1H),7.57-7.23(m,2H),7.20(m,2H),7.09( m,1H),6.82-6.79(m,2H),6.64(d,J=4.5Hz,1H),6.38-6.35(m,2H),3.87-3.83(m,3H),3.20-3.1 6(s,2H),2.94(s,3H),2.91-2.79(m,2H),2.15-2.06(m,4H),1.52-1.49(m,5H),1.44-1.40(m,2H ),1.35-1.29(m,12H),1.28(s.3H),1.02-0.95(m,2H),0.90-0.89(m,2H),0.70-0.64(m,2H)ppm. HR-MS(ESI + ): Calculated value C 51 H 55 FN 10 O6S[M+H] + :955.4044, measured value 955.4012.

[0271] Example 11: Synthesis of Compound 01

[0272]

[0273] The preparation method was similar to that of Example 1, except that 5-bromo-2-thiopyridine and iodomethane were used to replace 2-mercapto-5-bromofluorobenzene and bromocyclopropane to obtain compound 01. MS (ESI) [M+H] + :887.3418.

[0274] Example 12: Synthesis of Compound 02

[0275]

[0276] The preparation method is similar to that of Example 1, except that iodomethane is used to replace bromocyclopropane to obtain compound 02. MS (ESI) [M+H] + :915.3731.

[0277] Example 13: Synthesis of Compound 03

[0278]

[0279] The preparation method is similar to Example 3, except that iodomethane is used to replace bromocyclopropane to obtain compound 03. MS (ESI) [M+H] + :904.3372.

[0280] Example 14: Synthesis of Compound 04

[0281]

[0282] The preparation method is similar to that of Example 5, except that methylboronic acid is replaced by cyclopropaneboronic acid to obtain compound 04. MS (ESI) [M+H] + :955.4044.

[0283] Example 15: Synthesis of Compound 05

[0284]

[0285] The preparation method is similar to that of Example 5, except that methylboronic acid and bromocyclopropane were replaced by cyclopropaneboronic acid and iodomethane to obtain compound 05. MS (ESI) [M+H] + :944.3685.

[0286] Example 16: Synthesis of Compound 06

[0287]

[0288] The preparation method is similar to Example 5, except that iodomethane is used to replace bromocyclopropane to obtain compound 06. MS (ESI) [M+H] + :929.3888.

[0289] Example 17: Synthesis of Compound 07

[0290]

[0291] The preparation method is similar to Example 5, except that iodomethane is used to replace bromocyclopropane to obtain compound 07. MS (ESI) [M+H] + :918.3528.

[0292] Example 18: Synthesis of Compound 08

[0293]

[0294] The preparation method is similar to Example 6, except that iodomethane is used to replace bromocyclopropane to obtain compound 08. MS (ESI) [M+H] + :940.3684.

[0295] Example 19: Synthesis of Compound 09

[0296]

[0297] The preparation method is similar to that of Example 3, except that iodomethane is used to replace bromocyclopropane to obtain compound 09. MS (ESI) [M+H] + :925.3575.

[0298] Example 20: Synthesis of Compound 10

[0299]

[0300] The preparation method is similar to that of Example 1, except that 5-bromo-2-mercaptopyridine is used to replace 2-mercapto-5-bromofluorobenzene to obtain compound 10. MS (ESI) [M+H] + :913.3575.

[0301] Example 21: Synthesis of Compound 13

[0302]

[0303] The preparation method is similar to that of Example 5, except that methylboronic acid is replaced by cyclopropaneboronic acid to obtain compound 13. MS (ESI) [M+H] + :981.4201.

[0304] Example 22: Synthesis of Compound 14

[0305]

[0306] The preparation method is similar to that of Example 3, except that methylboronic acid is replaced by cyclopropaneboronic acid to obtain compound 14. MS (ESI) [M+H] + :970.3841.

[0307] Example 23: Synthesis of Compound 16

[0308]

[0309] The preparation method is similar to that of Example 3, except that the intermediate does not need to react with methylamine hydrochloride and directly reacts with intermediate 7c to obtain compound 16. MS (ESI) [M+H] + :944.3685.

[0310] Example 24: Synthesis of Compound 18

[0311]

[0312] The preparation method is similar to that of Example 6, except that the intermediate does not need to react with methylamine hydrochloride and directly reacts with intermediate 7c to obtain compound 18. MS (ESI) [M+H] + :955.3481.

[0313] Example 25: Synthesis of Compound 19

[0314]

[0315] The preparation method is similar to that of Example 1, except that 4-bromo-2-chlorobenzene-1-thiol is used to replace 2-mercapto-5-bromofluorobenzene to obtain compound 19. MS (ESI) [M+H] + :946.3233.

[0316] Example 26: Synthesis of Compound 20

[0317]

[0318] The preparation method is similar to that of Example 1, except that 4-bromo-3-chlorobenzenethiol is used to replace 2-mercapto-5-bromofluorobenzene to obtain compound 20. MS (ESI) [M+H] + :946.3233.

[0319] Example 27: Synthesis of Compound 21

[0320]

[0321] The preparation method is similar to that of Example 1, except that 4-bromo-2-methoxy-1-thiol is used to replace 2-mercapto-5-bromofluorobenzene to obtain compound 21. MS (ESI) [M+H] + :942.3278.

[0322] Example 28: Synthesis of Compound 22

[0323]

[0324] The preparation method was similar to that of Example 1, except that 4-bromo-3-methoxythiol was used to replace 2-mercapto-5-bromofluorobenzene to obtain compound 22. MS (ESI) [M+H]+ :942.3278.

[0325] Example 29: Synthesis of Compound 23

[0326]

[0327] The preparation method was similar to that of Example 1, except that 3-trifluoromethyl-4-bromothiophenol was used to replace 2-mercapto-5-bromofluorobenzene to obtain compound 20. MS (ESI) [M+H] + :980.3496.

[0328] Example 30: Synthesis of Compound 24

[0329]

[0330] The preparation method is similar to that of Example 1, except that 4-bromo-2-(trifluoromethyl)benzenethiol is used to replace 2-mercapto-5-bromofluorobenzene to obtain compound 24. MS (ESI) [M+H] + :980.3496.

[0331] Example 31: Synthesis of Compound 25

[0332]

[0333] The preparation method was similar to that of Example 1, except that 4-bromo-3-fluorothiophenol was used to replace 2-mercapto-5-bromofluorobenzene to obtain compound 25. MS (ESI) [M+H] + :930.3528.

[0334] Example 32: Synthesis of Compound 26

[0335]

[0336] The preparation method is similar to that of Example 1, except that 3-bromo-2-fluorobenzenethiol is used to replace 2-mercapto-5-bromofluorobenzene to obtain compound 26. MS (ESI) [M+H] + :930.3528.

[0337] Example 33: Synthesis of Compound 27

[0338]

[0339] The preparation method is similar to that of Example 1, except that 5-bromo-2-fluorobenzenethiol is used to replace 2-mercapto-5-bromofluorobenzene to obtain compound 27. MS (ESI) [M+H] + :930.3528.

[0340] Example 34: Synthesis of Compound 28

[0341]

[0342] The preparation method is similar to Example 7, except that 5-bromo-2-(bromomethyl)pyridine is used to replace 2-fluoro-4-bromobenzyl bromide to obtain compound 20. MS (ESI) [M+H] + :927.3731.

[0343] Example 35: Synthesis of Compound 30

[0344]

[0345] The preparation method is similar to Example 7, except that the intermediate does not need to react with methylamine hydrochloride and directly reacts with intermediate 7c to obtain compound 30. MS (ESI) [M+H] + :944.3685.

[0346] Example 36: Synthesis of Compound 31

[0347]

[0348] The preparation method is as in Examples 5 and 7, except that methylboronic acid is replaced by cyclopropaneboronic acid to obtain compound 31, MS (ESI) [M+H] + :995.4357.

[0349] Example 37: Synthesis of Compound 32

[0350]

[0351] The preparation method refers to Examples 5 and 7, except that methylboronic acid is replaced by cyclopropaneboronic acid, and the intermediate does not need to react with methylamine hydrochloride, but directly reacts with intermediate 7c to obtain compound 32, MS (ESI) [M+H] + :980.4248.

[0352] Example 38: Synthesis of Compound 33

[0353]

[0354] Preparation method: Reference Examples 5 and 7, MS (ESI) [M+H] + :969.4201.

[0355] Example 39: Synthesis of Compound 34

[0356]

[0357] The preparation method is similar to that of Examples 5 and 7, except that the intermediate does not need to react with methylamine hydrochloride, but directly reacts with intermediate 7c to obtain compound 34, MS (ESI) [M+H] + :958.3841.

[0358] Example 40: Synthesis of Compound 35

[0359]

[0360] The preparation method is similar to Example 6, except that iodomethane is used to replace bromocyclopropane to obtain compound 35. MS (ESI) [M+H] + :940.3684.

[0361] Example 41: Synthesis of Compound 36

[0362]

[0363] The preparation method is similar to Example 6, except that iodomethane is used to replace bromocyclopropane, and the intermediate does not need to react with methylamine hydrochloride, but directly reacts with intermediate 7c to obtain compound 36, MS (ESI) [M+H] + :929.3324.

[0364] Example 42: Synthesis of Compound 37

[0365]

[0366] The preparation method is based on Examples 7 and 8, except that 2-bromo-5-(bromomethyl)pyridine is used to replace 2-fluoro-4-bromobenzyl bromide to obtain compound 37. MS (ESI) [M+H] + :901.3575.

[0367] Example 43: Synthesis of Compound 38

[0368]

[0369] The preparation method is similar to that of Example 8, except that the intermediate 14a is reacted with methylamine hydrochloride and then reacted with intermediate 7c to obtain compound 38. MS (ESI) [M+H] + :929.3888.

[0370] Example 44: Synthesis of Compound 40

[0371]

[0372] The preparation method is similar to that of Example 1, except that bromocyclobutane is used to replace bromocyclopropane to obtain compound 40. MS (ESI) [M+H] +:955.4044.

[0373] Example 45: Synthesis of Compound 41

[0374]

[0375] The preparation method is similar to that of Example 1, except that 3-bromooxetane is used to replace bromocyclopropane to obtain compound 41. MS (ESI) [M+H] + :957.3837.

[0376] Example 46: Synthesis of Compound 42

[0377]

[0378] The preparation method was similar to that of Example 1, except that trifluoroiodomethane was used to replace bromocyclopropane to obtain compound 42. MS (ESI) [M+H] + :969.3449.

[0379] Example 47: Synthesis of Compound 43

[0380]

[0381] The preparation method refers to Example 1, except that 5-bromo-2,3-dihydrobenzo[b]thiophene is used as the raw material. MS (ESI) [M+H] + :938.3779.

[0382] Example 48: Synthesis of Compound 44

[0383]

[0384] The preparation method refers to Example 1, except that 5-bromo-2-mercaptobenzamide was used as the raw material. MS (ESI) [M+H] + :912.3258.

[0385] Example 49: Synthesis of Compound 45

[0386]

[0387] The preparation method refers to Example 1, except that 2,5-dibromobenzaldehyde and dimethylsulfenyl imide hydrochloride are used as raw materials. MS (ESI) [M+H] + :910.3466.

[0388] Example 50: Synthesis of Compound 46

[0389]

[0390] Preparation method: Refer to the synthesis of intermediate 2d in Example 1, except that 1-cyclopropyl-1H-pyrazole-4-amine was used to replace 3-bromo-4-fluoroaniline to obtain compound 46. MS (ESI) [M+H] + :902.3527.

[0391] Example 51: Synthesis of Compound 47

[0392]

[0393] Preparation method: Refer to the synthesis of intermediate 2d in Example 1, except that 2-amino-3-fluoro-5-chloropyridine was used to replace 3-bromo-4-fluoroaniline to obtain compound 47. MS (ESI) [M+H] + :925.2778.

[0394] Example 52: Synthesis of Compound 48

[0395]

[0396] Preparation method: Refer to the synthesis of intermediate 2d in Example 1, except that 1-methyl-1H-indazol-5-amine was used to replace 3-bromo-4-fluoroaniline to obtain compound 48. MS (ESI) [M+H] + :926.3527.

[0397] Example 53: Measurement of in vitro cAMP signaling activation by compounds in human GLP-1R cells

[0398] 1. Experimental Methods

[0399] 1. Cell culture

[0400] The CHO cell line stably expressing human GLP-1R (purchased from Beijing Aisiyipu Biotechnology Co., Ltd.) was cultured in F-12 medium (Gibco) containing 10% fetal bovine serum + 200 μg / mL Hygromycin B medium at 37°C and a carbon dioxide concentration of 5%.

[0401] 2. cAMP determination

[0402] Stable transfected cells expressing human GLP-1R receptor were incubated with test compounds at different concentrations, and the agonism of the compounds on human GLP-1R receptor was determined using the TR-FRET cAMP kit (purchased from PerkinElmer, catalog number: TRF0264).

[0403] (1) Prepare 1× Stimulation Buffer according to the kit instructions.

[0404] (2) The positive compound GLP1 (7-37) purchased from Shanghai Aladdin was serially diluted with DMSO to 10 concentrations (initial concentration was 100 nM), and the test compound was serially diluted to 5 concentrations (initial concentration was 10000 nM), and then diluted to 10× with 1× Stimulation Buffer.

[0405] (3) Stably transfected cells were cultured to 80% confluency, and the cells were collected by trypsin digestion. After counting, 9 μL / well was inoculated into a 384-well plate.

[0406] (4) Take 1 μL of the 10× compound diluted in step (2) and add it to the corresponding experimental well. After centrifugation, incubate at 37°C for 30 minutes.

[0407] (5) Dilute the Eu-cAMP in the kit to the working concentration with detection buffer and add 5 μL / well to the corresponding experimental wells.

[0408] (6) Dilute the Light-anti-cAMP in the kit to the working concentration with detection buffer, then add 5 μL / well to the corresponding experimental wells; centrifuge and incubate at room temperature for 1 hour.

[0409] (7) After the incubation is completed, the readings at 665 nm and 620 nm are detected using an ELISA reader under excitation at a wavelength of 330 nm.

[0410] 3. Data processing

[0411] Calculate the ratio of donor to acceptor emission signals for each well: HTRF ratio = 665nm signal / 620nm signal * 10 4 , and then the HTRF rate was converted into reaction rate (%);

[0412] The following nonlinear fitting formula was used to create the concentration-response curve of each example compound and calculate the half-maximal (50%) effective concentration (EC 50 ), and data were analyzed using Graphpad 7.0 software.

[0413] Y=Bottom+(Top-Bottom) / (1+10^((LogEC 50 -X)×HillSlope))

[0414] 2. Experimental Results

[0415] The agonist activity of the compounds of the present invention on GLP-1 receptor is shown in Table 1:

[0416] Table 1 EC of some compounds of the present invention for GLP-1 receptor agonist activity 50Value (nM)

[0417]

[0418]

[0419] Note: A: 0-10nM, B: 10-100nM, C>100nM;

[0420] Conclusion: The compounds of the present invention have significant agonist activity on human GLP-1R. Therefore, the compounds of the present invention can be used as small molecule agonists of GLP-1 receptor.

[0421] Positive Control:

[0422]

[0423] The positive control was synthesized according to patent WO2018056453.

[0424] Example 54: Determination of metabolic stability of the compounds of the present invention in rat liver microsomes in vitro

[0425] 1. Experimental Methods

[0426] RLM was extracted from the liver of SD rats and diluted to 5 mg / mL with PBS buffer. MgCl2 and NADPH were weighed and prepared into 20 mM and 4 mM solutions with PBS buffer. PBS, MgCl2, compound, and RLM were added to a 1.5 mL EP tube in order, vortexed gently, and incubated at 37°C in a constant temperature water bath for 5 min. After incubation, NADPH was added to start the reaction, and 200 μL of ethyl acetate was added at 0, 5, 15, 30, 60, and 120 min to terminate the reaction. After centrifugation at 4°C and 12000 rpm for 5 min, the supernatant was taken and transferred to another set of sample tubes for evaporation. Finally, 100 μL of acetonitrile containing internal standard (20 ng / mL diazepam) was added for reconstitution, vortexed, and analyzed by LC-MS / MS injection.

[0427] 2. Experimental Results

[0428] The results of the metabolic stability test of the compounds of the present invention on rat liver microsomes are shown in Table 2

[0429] Table 2 Metabolic stability results of some compounds in the present invention in rat liver microsomes

[0430] Compound No. <![CDATA[t 1 / 2 (h)]]> <![CDATA[Cl in vitro (μL·min -1 ·mg protein -1 )]]> 12a 3.22 7.18 12b 3.99 6.68 39 3.83 6.85 Positive Control 1.99 11.59

[0431] Conclusion: The compounds of the present invention have better rat liver microsome stability than the reference compounds.

[0432] Positive Control:

[0433]

[0434] As described above, although the present invention has been shown and described with reference to specific preferred embodiments, it should not be construed as limiting the present invention itself. Various changes in form and details may be made without departing from the spirit and scope of the present invention as defined in the appended claims.

Claims

1. A sulfenyl imine compound of formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or hydrate thereof: in, Ring A is C 3-6 Cycloalkyl, C 6-10 Aryl or C 5-10 Heteroaryl; the cycloalkyl, aryl or heteroaryl may be optionally substituted by 1 to 5 independently selected from halogen, CN, NO2, C 1-6 Alkyl, C 3-6 Cycloalkyl or C 1-6 The substituent of the alkoxy group is substituted; the C 1-6 The alkyl group is optionally substituted with one or more halogen atoms; Ring B is phenyl, C 5-6 Heteroaryl or C 4-7 Heterocyclic group; the phenyl, heteroaryl or heterocyclic group may be optionally replaced by R 3 replace; R 1 Selected from hydrogen, deuterium, CN, C 1-6 Alkyl, C 3-6 Cycloalkyl or C 4-7 Heterocyclic group; the alkyl, cycloalkyl, heterocyclic group can be optionally substituted by halogen, CN, hydroxyl, C 1-3 Alkyl, C 3-6 Cycloalkyl, C 4-7 Heterocyclyl substitution; R 2 Selected from C 1-6 Alkyl, C 3-6 Cycloalkyl or C 4-7 Heterocyclic group, or R 1 , R 2 The atoms connected to it together form a 5-7 membered heterocyclic group; the alkyl, cycloalkyl, heterocyclic group may be optionally substituted by halogen, CN, hydroxyl, C 1-3 Alkyl, C 3-6 Cycloalkyl, 4-7 membered heterocyclic substitution; R 3 Selected from H, halogen, hydroxyl, -CN, -NO2, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -NHC 3-6 Cycloalkyl, -N(C 1-6 Alkyl)(C 3-6 Cycloalkyl), -C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -OC 3-6 Cycloalkyl, -OC 4-6 Heterocyclic group, -C(O)C 1-6 Alkyl, -C(O)C 4-6 Heterocyclic group, -CONH2, -CONH(C 1-6 Alkyl), -CON(C 1-6 Alkyl)2, -CONHC 3-6 Cycloalkyl, -CONHC 4-6 Heterocyclic group, -NHCOC 1-6 Alkyl, -NHCOOC 1-6 Alkyl, -NHCOC 3-6 Cycloalkyl, -NHCOOC 4-6 Heterocyclic group, -S(O)(=NC 1-6 Alkyl)C 1-6 Alkyl, -N=S(O)(C 1-6 Alkyl)2, -P(O)(C 1-6 Alkyl)2, C 1-6 Alkyl, C 3-8 Cycloalkyl, C 1-6 Alkoxy, C 6-10 Aryl, C 5-10 Heteroaryl or C 3-8 Heterocyclic group, or R 2 , R 3 Together with the atoms to which it is attached, it forms a 5-7 membered heterocyclic group; or R 1 , R 3 The atoms to which it is attached together form a 5-7 membered heterocyclic group; the alkyl, cycloalkyl, alkenyl, alkynyl, heterocyclic group, aryl or heteroaryl group may be optionally substituted by halogen, CN, hydroxyl, amino, nitro, acyl, C 1-6 Alkyl, -OC 1-6 Alkyl, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, C 3-6 Cycloalkyl, C 4-7 Heterocyclyl substitution; L 1 Does not exist, or L 1 Selected from (CH2) n -、-CH 0-1 R 4 (CH2) n -、-(CH2) n -O-CHR 4 -、-(CH2) n -NH-CHR 4 -; where R 4 is selected from hydrogen, halogen, hydroxy, alkyl, haloalkyl, alkoxy, haloalkoxy, alkoxyalkyl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl or alkylheterocycloalkyl; L 2 Selected from -C(=O)-, -CHR 5 - or -S(=O)2-; wherein R 5 is hydrogen, halogen or C 1-6 alkyl; Ring C is selected from the following groups: R 6 , R 7 , R 8 , R 9 are independently selected from hydrogen, halogen or C 1-6 alkyl; L 3 Does not exist, or L 3 Selected from -CH2-; L 4 Does not exist, or L 4 Selected from -CH2-; R 10a , R 10b are independently selected from hydrogen or C 1-6 Alkyl, where C 1-6 The alkyl group may be substituted with one or more halogen or C 1-6 Alkoxy substituted; or R 10a , R 10b Together with the carbon atoms to which they are attached, they can form C 3-15 Cycloalkyl, wherein C 3-15 The cycloalkyl group may be optionally substituted with halogen, CN, hydroxy, amino, nitro, C 1-3 Alkyl, C 3-6 Cycloalkyl, 4-7 membered heterocyclic substitution; R 11 Selected from the following groups: R 12a , R 12b , R 12c , R 12d , R 12e are each independently selected from hydrogen, C 1-6 Alkyl; among which C 1-6 The alkyl group may be substituted with one or more halogen or C 1-6 Alkoxy substitution; Ring D is C 3-12 Heterocyclic group, C 5-6 Heteroaryl; the heterocyclic group, heteroaryl group can be optionally substituted by halogen, CN, hydroxyl, amino, nitro, C 1-6 Alkyl, C 3-15 Cycloalkyl, C 4-7 Heterocyclyl substitution; n=0, 1 or 2.

2. The compound according to claim 1, characterized in that Ring C is selected from:

3. The compound according to claim 1, characterized in that Ring D is selected from:

4. The compound according to claim 1, characterized in that It has a structure shown in Formula Ia or Formula Ib: in, Ring A, Ring B, R 1 , R 2 , L 1 As defined in Formula I.

5. The compound according to claim 4, characterized in that Ring A is selected from phenyl or C 5-6 heteroaryl, and the phenyl or heteroaryl is substituted by 1 to 4 independently selected from halogen, C 1-6 Alkyl or C 3-6 The cycloalkyl group is substituted with a substituent.

6. The compound according to claim 4, characterized in that Structural unit Selected from:

7. The compound according to claim 1, characterized in that Selected from:

8. A pharmaceutical composition, characterized in that Comprising the compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt, stereoisomer, solvate, hydrate thereof and a pharmaceutically acceptable carrier.

9. Use of the compound according to any one of claims 1 to 7 in the preparation of a medicament for preventing and / or treating a GLP-1-mediated disease or a related disease.

10. The use according to claim 9, characterized in that: The GLP-1 mediated diseases or related diseases include diabetes, hyperglycemia, insulin resistance, glucose intolerance, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, adipocyte dysfunction, obesity, dyslipidemia, and hyperinsulinemia.

Citation Information

Cited By

  • Heterocyclic GLP-1R agonists

    US12617783B2